nosed with AML can be cured. With conventional chemotherapy 70% of the patients in the group under study will relapse within two years and current therapy is devastating in older adults; and 2) Chronic myeloid leukemia (CML) is a type of cancer that causes the body to produce large numbers of immature and mature white blood cells (myelocytes). Approximately 85% of patients with CML are in the chronic phase at the time of diagnosis. Ultimately, in the absence of curative treatment, the disease progresses to an accelerated phase where median survival is around 3-5 years. Chronic myeloid leukemia can occur at any age, but it more commonly affects middle-aged and older people.
About the University of Southampton
The University of Southampton is a leading UK teaching and research institution with a global reputation for leading-edge research and scholarship across a wide range of subjects in engineering, science, social sciences, health and humanities.
With over 23,000 students, around 5000 staff, and an annual turnover well in excess of £435 million, the University of Southampton is acknowledged as one of the country's top institutions for engineering, computer science and medicine. We combine academic excellence with an innovative and entrepreneurial approach to research, supporting a culture that engages and challenges students and staff in their pursuit of learning.
The University is also home to a number of world-leading research centres including the Institute of Sound and Vibration Research, the Optoelectronics Research Centre, the Web Science Trust and Doctoral training Centre, the Centre for the Developmental Origins of Health and Disease, the Southampton Statistical Sciences Research Institute and is a partner of the National Oceanography Centre at the Southampton waterfront campus.
About Inovio Pharmaceuticals, Inc.
Inovio is revolutionizing vaccines to prevent and treat today's cancers and challengi
Page: 1 2 3 4 5 6 7 Related biology technology :1
|SOURCE Inovio Pharmaceuticals, Inc.|
Copyright©2012 PR Newswire.
All rights reserved
. Inovio Pharmaceuticals Cytomegalovirus (CMV) Synthetic Vaccine Constructs Generate Strong and Broad T-Cell Responses in Preclinical Study2
. Inovio Pharmaceuticals to Present at Noble Financial Life Sciences Conference3
. Inovios Scientific Advisory Board Chairman Elected as a Fellow by the American Association for the Advancement of Science4
. Inovio Pharmaceuticals to Present at Noble Financial 8th Annual Equity Conference5
. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer6
. Gallus BioPharmaceuticals Announces Appointment of Senior Baxter Executive as Chief Commercial Officer7
. Ampio Pharmaceuticals, Inc. (AMPE) announces appointment of Josh Disbrow as Chief Operating Officer effective December 15, 20128
. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Update and Reports Financial Results for Third Quarter 20129
. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results10
. Vanda Pharmaceuticals to Present at the Lazard Healthcare Conference11
. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess of $100,000 Investing In Keryx Biopharmaceuticals, Inc. To Contact the Firm